# Leqvio (inclisiran sodium) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/inclisiran

> The FDA approved Leqvio (inclisiran sodium), sponsored by NOVARTIS AG (NVS), on December 22, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Leqvio (inclisiran sodium) |
| Codes | KJX839 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [Acute Coronary Syndrome](https://sec-api.dev/indications/acute-coronary-syndrome), [Familial Hypercholesterolemia - Homozygous](https://sec-api.dev/indications/familial-hypercholesterolemia-homozygous), [Atherosclerotic Cardiovascular Disease (ASCVD)](https://sec-api.dev/indications/atherosclerotic-cardiovascular-disease-ascvd), [Atherosclerotic Cardiovascular Disease](https://sec-api.dev/indications/atherosclerotic-cardiovascular-disease), [Primary Prevention of Atherosclerotic Cardiovascular Disease](https://sec-api.dev/indications/primary-prevention-of-atherosclerotic-cardiovascular-disease), [Hypercholesterolaemia](https://sec-api.dev/indications/hypercholesterolaemia), [Familial Hypercholesterolemia - Heterozygous](https://sec-api.dev/indications/familial-hypercholesterolemia-heterozygous), [Coronary Artery Disease](https://sec-api.dev/indications/coronary-artery-disease) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### December 18, 2020: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22214012_2022_Orig1s000OtherActionLtrs.pdf%22

### December 22, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214012 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211222, review_priority STANDARD; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22

### July 31, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214012 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20250731, review_priority STANDARD; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22

### February 12, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214012 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260212, review_priority PRIORITY; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22
- openFDA Drugs@FDA: "NDA214012 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20260212, review_priority PRIORITY; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Coronary Artery Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05360446

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Coronary Artery Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05360446

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Acute Coronary Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07102628

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Acute Coronary Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07102628

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hypercholesterolaemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07610278

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hypercholesterolaemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT07610278

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atherosclerotic Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05030428 (Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05030428

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atherosclerotic Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05030428 (Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05030428

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atherosclerotic Cardiovascular Disease (ASCVD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06813911 (Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06813911

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atherosclerotic Cardiovascular Disease (ASCVD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06813911 (Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06813911

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Familial Hypercholesterolemia - Homozygous.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06597006 (Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06597006

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Familial Hypercholesterolemia - Heterozygous.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06597019 (Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06597019

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Familial Hypercholesterolemia - Homozygous.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06597006 (Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06597006

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Familial Hypercholesterolemia - Heterozygous.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06597019 (Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT06597019

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Primary Prevention of Atherosclerotic Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05739383 (A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05739383

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Primary Prevention of Atherosclerotic Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05739383 (A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT05739383

## Same indication

- [Humacyte coronary tissue engineered vessel (ctev)](https://sec-api.dev/pdufa/humacyte-coronary-tissue-engineered-vessel-ctev) (HUMA)
- [Laroprovstat](https://sec-api.dev/pdufa/laroprovstat) (AZN)
- [Laroprovstat/rosuvastatin 1](https://sec-api.dev/pdufa/laroprovstat-rosuvastatin-1) (AZN)
- [Lepodisiran](https://sec-api.dev/pdufa/lepodisiran) (LLY)
- [Maridebart cafraglutide](https://sec-api.dev/pdufa/maridebart-cafraglutide) (AMGN)
- [Milvexian](https://sec-api.dev/pdufa/milvexian) (JNJ)
- [Obicetrapib](https://sec-api.dev/pdufa/obicetrapib) (NAMS)
- [Olpasiran](https://sec-api.dev/pdufa/olpasiran) (AMGN)
- [Retatrutide](https://sec-api.dev/pdufa/retatrutide) (LLY)
- [YMI024](https://sec-api.dev/pdufa/ymi024) (NVS)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [February 2027](https://sec-api.dev/fda-calendar/2027-02), [April 2027](https://sec-api.dev/fda-calendar/2027-04), [May 2027](https://sec-api.dev/fda-calendar/2027-05), [February 2028](https://sec-api.dev/fda-calendar/2028-02), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/inclisiran.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Leqvio (inclisiran sodium) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/inclisiran

```bibtex
@misc{secapidev_pdufa_inclisiran_20261116,
  title        = {Leqvio (inclisiran sodium) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/inclisiran}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_inclisiran_20261116","title":"Leqvio (inclisiran sodium) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/inclisiran","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
